Global

The EC's latest proposals have thrown water on Europe's firey Direct-to-Consumer advertising debate. But is it enough to keep the flames at bay?

Richard Pops, Chief Executive Officer of Alkermes, explains how the company has established itself as a global, Irish-based firm.

GxP Cloud - business enablement for Life Sciences

Y.K. Hamied, PhD, Chairman, Cipla

Success in the emerging markets depends significantly on navigating the myths and mental traps.

Sir Michael Rawlins, Chairman of the UK National Institute for Health and Clinical Excellence

Garbo gets it ...

Big Pharma has increasingly turned to strategic outsourcing models to realize their own enterprise-wide strategic goals. Small- and medium-sized companies need to follow suit.

Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health?

Pharm Exec talks to Dr. Mel Spigelman, President and CEO of the TB Alliance, about the organization's tuberculosis priorities.

Tata Consultancy Services has grown into one of the largest IT solutions providers in the world

Richard Barker, former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.

Within an industry that traditionally moves at a slow pace, the rapidly changing playing field as required both Indian pharmaceutical companies, as well as MNCs, to adjust their strategies accordingly

Especially when payers come to the table holding the best cards - leaving industry second-guessing its strategy.

Q&A with Satish, Reddy, MD, COO of Dr. Reddy's Labs

When it comes to the emerging markets, executing a few key elements of success are more important than ever.

A Q&A with Kristin Peck, the drugmaker's Executive Vice President, Worldwide Business Development and Innovation.

What Big Pharma fails to see is how engagement in health policy is the biggest of reputation builders

Having progressively improved its financial standings over the past decade, this Eastern European market is now a bastion of potential-to the tune of $1.2 billion

HTAs are gridlocked by diverse national requirements, a lack of alignment on processes, and even on the value of their outcomes.

What India's latest census tells us about current and future pharma opportunities.

While Europe's EFPIA preaches about embracing change, much remains to be done to prove the adjustment in philosophy

A country that bridges East and West, old and new-while boasting a growing economy in Europe-is being looked to for its pool of talented industry resources

Survey on European market access trends says the most challenging factor in the pharma industry is switching focus on marketing to the payer rather than the prescriber.

GlaxoSmithKline has entered into an agreement to purchase Shenzhen Neptunus? stake in a previously formed joint venture between the companies involved in the development and manufacture of influenza vaccines in China, Hong Kong, and Macau.